Establishment Labs to Announce Fourth Quarter 2020 Financial Results on March 10

Rhea-AI Summary

Establishment Labs Holdings (NASDAQ: ESTA) is set to announce its financial results for Q4 2020 on March 10, 2021, before market open. A conference call will follow at 8:30 AM ET to discuss these results. The company specializes in women’s health, primarily in breast aesthetics, with its innovative Motiva Implants® and related technologies. Products are available in over 80 countries, adhering to strict regulatory standards. The company also initiated a clinical trial in the U.S. for Motiva Implants® after receiving FDA approval in March 2018.

Positive

• Innovative product portfolio including Motiva Implants®.
• Available in over 80 countries, indicating strong global presence.
• Compliance with regulatory standards (ISO13485:2016, FDA 21 CFR 820).

Negative

• None.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended December 31, 2020 before the market opens on Wednesday, March 10, 2021, and will host a conference call at 8:30 am ET that day to discuss those results.

To participate in the conference call, dial (877) 376-9925 (U.S. and Canada) or (629) 228-0732 (International) and use conference ID number 5664669. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com.

About Establishment Labs

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005022/en/

FAQ

When will Establishment Labs announce its financial results?

Establishment Labs will announce its financial results for the quarter ended December 31, 2020, on March 10, 2021.

What time is the Establishment Labs conference call?

The conference call will take place at 8:30 AM ET on March 10, 2021.

How can I participate in the Establishment Labs conference call?

You can participate by dialing (877) 376-9925 for U.S. and Canada or (629) 228-0732 for international calls.

What products does Establishment Labs focus on?

Establishment Labs focuses on women's health, particularly breast aesthetics, with products like Motiva Implants®.

What is the FDA status of Motiva Implants®?

Motiva Implants® received FDA approval for an investigational device exemption and are undergoing clinical trials in the U.S.